Eleni Aklillu
Professor | Forskargruppsledare
E-postadress: eleni.aklillu@ki.se
Telefon: +46852483556
Besöksadress: Widerströmska huset Tomtebodavägen 18 A, plan 3, 17165 Solna
Postadress: K9 Global folkhälsa, K9 GPH Aklillu, 171 77 Stockholm
Artiklar
- Journal article: LANCET MICROBE. 2027;:101442Marais BJ; Goletti D; McHugh TD; Tiberi S; Aklillu E; Yeboah-Manu D; Mfinanga S; Zumla A; Ahmed R; Hasan T; Nyasulu PS; Chakaya J; Ntoumi F; Walzl G; Hui DS; Zumla A
- Journal article: JOURNAL OF INFECTIOUS DISEASES. 2026;:jiag377Zerebinski J; Broumou I; Kimenyi KM; Aklillu E; Andrade CM; Babiker H; Bejon P; Cherif MK; Crompton PD; Fancony C; Foroogh F; Gil JP; Homann MV; Trovoada MDJ; Kapulu M; Kiwuwa SM; Kweku MA; Liljander A; Lopes D; Marsh K; Mutemi DD; Ngasala B; Normark J; Orikiiriza J; Persson KEM; Portugal S; Ribacke U; Sirima SB; Sonden K; de Sousa TN; Traore B; Tijani MK; Eckerdal N; Villner P; Ochola-Oyier LI; Plaza DF; Farnert A
- Article: INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES. 2025;161:108118Namwase H; Mukonzo JK; Ankunda C; Vella S; Tadesse BT; Aklillu E
- Journal article: LANCET INFECTIOUS DISEASES. 2025;25(12):1336-1346van Eijk AM; Stepniewska K; Khairallah C; Rodriguez E; Ahn J; Gutman JR; Ter Kuile FO; IPTp-SP Effectiveness Study group
- Article: JOURNAL OF PUBLIC HEALTH RESEARCH. 2025;14(3):22799036251361622Tadele T; Astatkie A; Tadesse BT; Makonnen E; Abay SM; Aklillu E
- Article: INFECTIOUS DISEASES OF POVERTY. 2025;14(1):11Khaemba C; Njenga SM; Omondi WP; Kirui E; Oluka M; Guantai A; Aklillu E
- Article: BMC PUBLIC HEALTH. 2024;24(1):3367Gedefaw A; Tadesse BT; Tadesse S; Kebede B; Hussen S; Hailu D; Berhan Y; Makonnen E; Vella S; Aklillu E
- Article: DRUG SAFETY. 2024;47(12):1193-1202van Puijenbroek E; Barry A; Khaemba C; Ntirenganya L; Gebreyesus TD; Fimbo A; Minzi O; Makonnen E; Oluka M; Guantai A; Aklillu E
- Article: BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 2024;90(11):2823-2836Mugusi S; Mnkugwe RH; Sanga AA; Salahuddin A; Barclay V; Shayo G; Dahl M-L; Aklillu E
- Article: BMC INFECTIOUS DISEASES. 2024;24(1):901Gedefaw A; Tadesse BT; Berhan Y; Makonnen E; Vella S; Aklillu E
- Article: BMC PHARMACOLOGY & TOXICOLOGY. 2024;25(1):38Mlugu EM; Minzi OMS; Johansson M; Kamuhabwa AAR; Aklillu E
- Article: INFECTIOUS DISEASES OF POVERTY. 2024;13(1):44Fimbo AM; Mnkugwe RH; Mlugu EM; Kunambi PP; Malishee A; Minzi OMS; Kamuhabwa AAR; Aklillu E
- Article: SCIENTIFIC REPORTS. 2024;14(1):11730Gebreyesus TD; Makonnen E; Telele NF; Barry A; Mnkugwe RH; Gerba H; Dahl M-L; Aklillu E
- Article: INFECTIOUS DISEASES. 2024;56(4):308-319Sileshi T; Makonnen E; Telele NF; Barclay V; Zumla A; Aklillu E
- Article: INFECTIOUS DISEASES OF POVERTY. 2024;13(1):8Gebreyesus TD; Makonnen E; Tadele T; Mekete K; Gashaw H; Gerba H; Aklillu E
- Article: TROPICAL MEDICINE AND HEALTH. 2023;51(1):72Tadele T; Astatkie A; Tadesse BT; Makonnen E; Aklillu E; Abay SM
- Article: CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY. 2023;12(12):1884-1896Fimbo AM; Mlugu EM; Kitabi EN; Kulwa GS; Iwodyah MA; Mnkugwe RH; Kunambi PP; Malishee A; Kamuhabwa AAR; Minzi OM; Aklillu E
- Article: DRUG SAFETY. 2023;46(10):961-974Khaemba C; Barry A; Omondi WP; Kirui E; Oluka M; Parthasarathi G; Njenga SM; Guantai A; Aklillu E
- Article: PATHOGENS. 2023;12(9):1170Kabatende J; Ntirenganya L; Mugisha M; Barry A; Ruberanziza E; Bienvenu E; Bergman U; Aklillu E
- Article: SCIENTIFIC REPORTS. 2023;13(1):11438Sileshi T; Telele NF; Burkley V; Makonnen E; Aklillu E
- Visa fler
Alla övriga publikationer
- Editorial: LANCET INFECTIOUS DISEASES. 2025;25(10):1066-1068Ntoumi F; Aklillu E; Asogun D; Ansumana R; Mfinanga S; Yeboah-Manu D; Nacheg JB; Zumla A
- Preprint: BIORXIV. 2025Zerebinski J; Broumou I; Kimenyi KM; Aklilu E; Andrade CM; Babiker H; Bejon P; Cherif MK; Crompton PD; Fançony C; Foroogh F; Gil JP; Kapulu M; Kiwuwa SM; Kweku MA; Liljander A; Lopes D; Marsh K; Mutemi DD; Ngasala B; Normark J; Orikiiriza J; Persson KEM; Portugal S; Ribacke U; Sirima SB; Sondén K; de Sousa TN; Traore B; Tijani MK; Eckerdal N; Villner P; Ochola-Oyier LI; Plaza DF; Färnert A
- Editorial: INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES. 2025;155:107901Mpabalwani E; Ippolito G; Asogun D; Aklillu E; Maeurer M; Lee SS; Zumla A
- Review: ECLINICALMEDICINE. 2025;83:103202Roh ME; Gutman JR; Murphy M; Hill J; Madanitsa M; Kakuru A; Barsosio HC; Kariuki S; Lusingu JPA; Mosha F; Kajubi R; Kamya MR; Mathanga D; Chinkhumba J; Laufer MK; Mlugu E; Kamuhabwa AAR; Aklillu E; Minzi O; Okoro RN; Geidam AD; Ohieku JD; Desai M; Jagannathan P; Dorsey G; ter Kuile FO
- Review: IJID REGIONS. 2025;14(Suppl 2):100576Ahmed R; Zumla A; Taylor E; Aklillu E; Ippolito G; Satta G
- Book chapter: SPECIAL ISSUES IN PHARMACOVIGILANCE IN RESOURCE-LIMITED COUNTRIES. 2025;p. 365-371Aklillu E; Nderu M
- Editorial: LANCET INFECTIOUS DISEASES. 2025;25(1):14-16Sahu S; Ditiu L; Ahmed R; Zumla A; Aklillu E; Singh UB; Yeboah-Manu D; Asogun D; Hui DS; Zumla A
- Preprint: MEDRXIV. 2024;MEDRXIVRoh ME; Gutman J; Murphy M; Hill J; Madanitsa M; Kakuru A; Barsosio HC; Kariuki S; Lusingu JPA; Mosha F; Kajubi R; Kamya MR; Mathanga D; Chinkhumba J; Laufer MK; Mlugu E; Kamuhabwa AAR; Aklillu E; Minzi O; Okoro RN; Geidam AD; Ohieku JD; Desai M; Jagannathan P; Dorsey G; Ter Kuile FO
- Letter: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2024;80(7):1111-1112Stingl J; Aklillu E; Masimirembwa C; Kek TL
- Review: INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES. 2024;141:107002Petersen E; Al-Abri S; Al-Jardani A; Memish ZA; Aklillu E; Ntoumi F; Mwaba P; Wejse C; Zumla A; Al-Yaquobi F
- Conference publication: BMJ GLOBAL HEALTH. 2023;8(SUPPL_10):a37.3-a3a38Khaemba C; Barry A; Omondi W; Kirui E; Mandale M; Oluka M; Gurumurthy P; Njenga S; Guantai A; Aklillu E
- Conference publication: BMJ GLOBAL HEALTH. 2023;8(SUPPL_10):a35.2-a3a35Fimbo AM; Minzi O; Aklillu E
- Conference publication: BMJ GLOBAL HEALTH. 2023;8(SUPPL_10):a32.1-a3a32Gebreyesus TD; Makonnen E; Tadele T; Mekete K; Gashaw H; Gerba H; Aklillu E
- Conference publication: BMJ GLOBAL HEALTH. 2023;8(SUPPL_10):a78.1-a7a78Tadesse BT; Birhan Y; Mekonnen E; Vella S; Aklillu E; Gedefaw A
- Editorial: INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES. 2023;131:180-182Petersen E; Hui DS; Nachega JB; Ntoumi F; Goletti D; Aklillu E; Sharma A; Nyirenda T; Yeboah-Manu D; Satta G; da Costa C; Azhar EI; Bockarie M; Al-Abri S; Mchugh TD; Rodriguez-Morales AJ; Varghese G; Zumla A
- Review: PHARMACOGENOMICS & PERSONALIZED MEDICINE. 2022;15:561-571Sileshi T; Mekonen G; Makonnen E; Aklillu E
- Editorial: LANCET RESPIRATORY MEDICINE. 2022;10(6):533-536Castro KG; Ditiu L; Sahu S; Ntoumi F; Tiberi S; O'Kane CM; Akkerman O; Manika K; Mwaba P; Forsman LD; Petersen E; Aklillu E; Azhar EI; Cirillo DM; Migliori G-B; Abbara A; Zumla A
- Editorial: LANCET INFECTIOUS DISEASES. 2022;22(4):442-444Ntoumi F; Nachega JB; Aklillu E; Chakaya J; Felker I; Amanullah F; Yeboah-Manu D; Castro KG; Zumla A
- Editorial: INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES. 2022;114:268-272Petersen E; Ntoumi F; Hui D; Abubakar A; Kramer LD; Obiero C; Tambyah PA; Blumberg L; Yapi R; Al-Abri S; Pinto TDCA; Yeboah-Manu D; Haider N; Asogun D; Velavan TP; Kapata N; Bates M; Ansumana R; Montaldo C; Mucheleng'anga L; Tembo J; Mwaba P; Himwaze C; Hamid MMA; Mfinanga S; Mboera L; Raj T; Aklillu E; Veas F; Edwards S; Kaleebu P; McHugh TD; Chakaya J; Nyirenda T; Bockarie M; Nyasulu PS; Wejse C; Muyembe-Tamfum J-J; Azhar EI; Maeurer M; Nachega JB; Kock R; Ippolito G; Zumla A
- Review: EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY. 2021;17(9):1125-1138Aklillu E; Engidawork E
- Visa fler
Forskningsbidrag
- European Commission1 juli 2024 - 30 juni 2027Why RER-CTO?: The conduct of clinical trials requires competent ethics committee and regulatory authorities that can review clinical trial applications and monitor processes independently and efficiently ensuring the safety of clinical trial participants, and the integrity and reliability of the generated data. The capacity of most African regulatory authorities regarding clinical trial review and oversight is weak due to poor infrastructure, limited resources both human and financial, lack of expertise, un-conducive working framework and lack of systems adequately supported by technology. Collaboration between academia, international organizations, National ethics committees (NECs) and national regulatory authorities (NRAs) are mandatory to produce sustainable regulatory skills and functional clinical trial oversight systems. The RER-CTO consortium consists of a group of well reputable clinical trial researchers, regulatory authorities, ethics committees, universities and research institutes in Ethiopia, Tanzania, Norway, and Sweden. Our aim is to achieve ethics and regulatory excellence and harmonization in sub-Saharan Africa in clinical trial oversight (CTO) by improving the legal and policy framework by identifying gaps and making recommendations, improving regulatory and research ethics oversight capacity and capability by digitalising the clinical trial oversight systems and developing training programs to strengthen competency of relevant stakeholders, and strengthening local, regional, and international collaborations and coordination of NECs and NRAs for clinical trial oversight by developing joint clinical trial review guidelines. These efforts are geared towards increasing clinical trials in sub-Saharan Africa, standardization of clinical trial review and monitoring processes, and promoting ownership, efficiency, linkages for data sharing, transparency, and accountability of clinical trial review processes.
- Global Health EDCTP3 Joint Undertaking11 juni 2024 - 10 juni 2027Africa’s regulatory authorities lack the resources and infrastructure to oversee clinical trials effectively. To address these challenges and improve oversight systems, collaboration between academia, international organisations, national ethics committees, and regulatory authorities is essential. The EU-funded RER-CTO project aims to enhance ethical and regulatory standards for trial oversight (CTO) in sub-Saharan Africa. It focuses on identifying gaps in the legal and policy framework, improving regulatory and research ethics oversight capacity through the digitalisation of CTO systems, developing training programmes, and fostering collaboration among NECs and NRAs to create joint clinical trial review guidelines. The project involves clinical trial researchers, regulatory authorities, ethics committees, universities, and research institutes from Ethiopia, Tanzania, Norway, and Sweden.
- Global Health EDCTP3 Joint Undertaking1 juni 2024 - 31 maj 2026
- European Commission1 juni 2023 - 31 maj 2026
- EDCTP1 juni 2018 - 31 december 2025
- European & Developing Countries Clinical Trials Partnership1 mars 2018 - 31 augusti 2024
- Swedish Research Council1 januari 2016 - 31 december 2019
- Swedish Research Council1 januari 2012 - 31 december 2014
- Swedish Research Council1 januari 2012 - 31 december 2014
- Swedish Research Council1 januari 2010 - 31 december 2012
Anställningar
- Professor, Tropikfarmakologi, Global folkhälsa, Karolinska Institutet, 2023-
- Professor, ME Infektion, Karolinska Universitetssjukhuset, 2023-
- Professor, Tropikfarmakologi, Laboratoriemedicin, Karolinska Institutet, 2020-2023
Examina och utbildning
- Docent, Farmakologi, Karolinska Institutet, 2009
- MEDICINE DOKTORSEXAMEN, Institutet för miljömedicin, Karolinska Institutet, 2003
Uppdrag
- Forskargruppsledare, Global Health Pharmacology and Therapeutics (GH-Pharma) – Eleni Aklillu's research group, Department of Global Public Health, Karolinska Institutet, 2023-
Handledning
Handledning till doktorsexamen
- Christabel Khaemba, Pharmacovigilance in mass drug administration for the control and elimination of lymphatic filariasis in Kenya, 2024
- Adam Mitangu Fimbo, Pharmacovigilance of mass drug administration as preventive chemotherapy to control and eliminate lymphatic filariasis in Tanzania, 2024
- Tigist Dires Gebreyesus, Pharmacovigilance of preventive chemotherapy for the control of schistosomiasis and soil-transmitted helminths in Ethiopia, 2023
- Joseph Kabatende, Pharmacovigilance of mass drug administration for the control of schistosomiasis and soil transmitted helminths in Rwanda., 2023
- Abbie Barry, Pharmacovigilance capacity in East Africa with focus on neglected tropical diseases., 2022
- Rajabu Hussein Mnkugwe., Novel combination chemotherapy for treatment and control of schistosomiasis among school children., 2021
- Eulambius Mathias Mlugu, Optimization of intermittent preventive therapy for malaria during pregnancy: effectiveness of dihydroartemisinin-piperaquine versus sulfadoxine-pyrimethamine., 2021
- Birkneh Tilahun Tadesse, Optimization of pediatrics antiretroviral treatment outcomes among HIV infected children in Ethiopia., 2020
- Wondwossen Amogne Degu, Optimization of TB/HIV co-treatment in Ethiopian patients, 2015
- Fazleen Haslinda Mohd Hatta, The impact of genetics, environmental, and geographical factors on inter-individual and inter-ethnic differences in CYP2C9-catalysed drug metabolism, 2015
- Eliford Ngaimisi Kitabi, Optimization of HIV and tuberculosis co-treatment in Tanzanian patients: emphasis on pharmacogenetics and drug interactions, 2013
- Abiy Habtewolde Eyakem, Pharmacokinetic and Pharmacogenetic aspects of drug-drug interactions between antiretroviral and anti-tuberculosis drugs in Ethiopian patients: Implication for optimization of TB-HIV co-treatment., 2013
- Sabina Mugusi, Optimization of HIV and tuberculosis co-treatment in Tanzania: drug-drug interactions and clinical outcomes., 2013
- Natasa Djordjevic, Importance of pharmacogenetic and environmental factors for variation in caffeine disposition: with special emphasis on CYP1A2, CYP2A6, NAT2 and XO., 2012
- Getnet Yimer Ali, Incidence, predictors and biomarkers for antiretroviral and/or anti-tuberculosis drugs induced liver injury., 2012
- Jackson Mukonzo., Pharmacogenetic aspects of HIV/AIDS, tuberculosis and malaria: emphasis on Ugandan population., 2011
- Annika Allqvist, The role of CYP3A4/5 in alprazolam metabolism., 2010
- Roza Ghotbi, Genetic, epigenetic and environmental factors of importance for CYP1A2 catalyzed drug metabolism., 2008
Handledning till licentiatexamen